Analystreport

NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at Piper Sandler from $180.00 to $130.00. They now have an "overweight" rating on the stock

NovoCure Limited - Ordinary Shares  (NVCR) 
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations